Joon Oh Park
A5045587524- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Gallbladder and Bile Duct Disorders
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Surgical Treatments
- Fibroblast Growth Factor Research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cancer, Lipids, and Metabolism
- Cancer Mechanisms and Therapy
- Renal cell carcinoma treatment
Samsung Medical Center
2016-2025
Sungkyunkwan University
2016-2025
University of Ulsan
2007-2025
Ulsan College
2025
Seoul Medical Center
2025
Seoul National University Hospital
2006-2024
Samsung (South Korea)
2018-2024
ABL Bio (South Korea)
2023
Merck Serono (Switzerland)
2023
AstraZeneca (Brazil)
2023
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive cancer cell line that developed resistance to as result of focal amplification the MET proto-oncogene. inhibition signaling in cells restored their sensitivity gefitinib. was detected 4 18 (22%) specimens had or erlotinib. We find causes by...
Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge investigate role of postoperative chemoradiotherapy therapy patients with curatively resected gastric cancer D2 lymph node dissection. This designed compare treatment capecitabine plus cisplatin (XP) versus XP radiotherapy (XP/XRT/XP). Patients and Methods arm received six cycles (capecitabine 2,000 mg/m 2 per day on days 1 14 60 1, repeated every 3 weeks) chemotherapy. XP/XRT/XP...
When designing this trial, there was no evidence that salvage chemotherapy (SLC) in advanced gastric cancer (AGC) resulted substantial prolongation of survival when compared with best supportive care (BSC). However, SLC is often offered to pretreated patients AGC for anecdotal reasons.Patients one or two prior regimens involving both fluoropyrimidines and platinum an Eastern Cooperative Oncology Group performance status (PS) 0 1 were randomly assigned a ratio 2:1 plus BSC alone. Choice...
To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma.Patients HER2-positive adenocarcinoma were randomly assigned at a one-to-one ratio CapeOx plus 1,250 mg or placebo daily. Primary end point was overall survival (OS) centrally confirmed HER2 amplification primary population.A total 545 assigned, 487 comprised population....
Objective: This study was performed to determine whether neoadjuvant treatment increases survival in patients with BRPC. Summary Background Data: Despite many promising retrospective data on the effect of for borderline resectable pancreatic cancer (BRPC), no high-level evidence exists support role such treatment. Methods: phase 2/3 multicenter randomized controlled trial designed enroll 110 BRPC who were randomly assigned gemcitabine-based chemoradiation (54 Gray external beam radiation)...
The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial tested whether the addition of radiotherapy to adjuvant chemotherapy improved disease-free survival (DFS) patients with D2-resected gastric cancer (GC).Between November 2004 and April 2008, 458 GC who received gastrectomy D2 lymph node dissection were randomly assigned either six cycles capecitabine cisplatin (XP) or two XP followed by chemoradiotherapy then additional (XPRT). This final update contains first publication overall...
To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA).HALO 109-301 was a phase III, randomized, double-blind, placebo-controlled study. Patients ≥ 18 years age untreated, metastatic, PDA were randomly assigned 2:1 to PEGPH20 AG or placebo AG. Treatment administered intravenously 4-week cycles (3 weeks on, 1 week off) until progression intolerable adverse...
Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared efficacy olaparib plus paclitaxel (olaparib/paclitaxel) alone in patients recurrent or metastatic gastric and assessed whether ATM expression is predictive improved clinical outcome for olaparib/paclitaxel. Patients Methods In this phase II, double-blind study (Study...
Adjuvant chemotherapy and chemoradiotherapy are some of the standards care for gastric cancer (GC). The chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant regimens in patients with D2-resected, stage II or III, node-positive GC.The ARTIST compared, a 1:1:1 ratio, three regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 off) 1 year, (2 on/1 week plus oxaliplatin 130 mg/m2 every 3 (SOX) 6 months, SOX 45 Gy (SOXRT). Randomization was stratified according to surgery...
Solid tumors such as pancreatic ductal adenocarcinoma (PDAC) comprise not just tumor cells but also a microenvironment with which the constantly interact. Detailed characterization of cellular composition is critical to understanding disease and treatment patient. Single-cell transcriptomics has been used study different solid types including PDAC. However, almost all those studies primary tissues.In this study, we employed single-cell RNA sequencing technology profile transcriptomes...
Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, responses broad spectrum tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head neck, breast cancer) bearing both known previously uncharacterized FGFR1-3 aberrations. The greatest activity observed FGFR2...
Abstract The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic based on clinical sequencing and focused eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, overexpression, all negative, TSC2 deficient, or RICTOR amplification) assign one of the 10 associated trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET selumetinib (MEK...
The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall (OS) other secondary end points.